All In Biotech

Drug Trial Radar · NCT00120523

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,418 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,418

Actual

Start

Apr 2004

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Lead sponsor
MEDA Pharma GmbH & Co. KGIndustry
Sponsor type
Industry
First posted
Jul 18, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 months, up to 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (TCS).

Conditions

  • Atopic Dermatitis

Interventions

  • PimecrolimusDrug

    Pimecrolimus cream 1 %

  • Topical corticosteroidsDrug

    TCS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Assessed by Adverse EventsTime frame: throughout the 5-year study
  2. Growth Velocity (Height)Time frame: throughout the 5-year study
  3. Growth Velocity (Weight)Time frame: throughout the 5-year study
  4. Potential Effect on the Developing Immune SystemTime frame: throughout the 5-year study

Locations

31 sites in 2 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Cholla Pediatrics

    Tucson, Arizona

  • Arkansas Pediatric Clinic

    Little Rock, Arkansas

  • Little Rock Allergy & Asthma Clinic

    Little Rock, Arkansas

  • 9540 Artesia Blvd., Suite #1

    Bellflower, California

  • Pediatric Care Medical Group, Inc.

    Huntington Beach, California

  • Longmont Clinical Research

    Longmont, Colorado

  • Children's Skin Center

    Miami, Florida

  • Pediatric Research Center of South Florida

    Palm Beach Gardens, Florida

  • AeroAllergy Research Laboratories of Savanah, Inc.

    Savannah, Georgia

  • The Pediatric Center

    Stone Mountain, Georgia

  • Wayne State University Dermatology

    Detroit, Michigan

  • Michigan State University - Kalamazoo Center for Med Studies

    Kalamazoo, Michigan

  • Respiratory Medicine Research Institute of Michigan

    Ypsilanti, Michigan

  • SMDC Health System

    Duluth, Minnesota

  • Dermatology Center for Children

    Minneapolis, Minnesota

  • University of Minnesota - Dept. of Dermatology

    Minneapolis, Minnesota

  • Radiant Research

    Bridgeton, Missouri

  • Dermatology Associates of Rochester, P.C.

    Rochester, New York

  • Capitol Pediatrics & Adolescent Center

    Raleigh, North Carolina

  • Dermatology Research Associates

    Cincinnati, Ohio

  • Ohio Pediatrics, Inc.

    Huber Heights, Ohio

  • The Portland Clinic

    Beaverton, Oregon

  • Calcagno Research and Development

    Gresham, Oregon

  • Allergy & Asthma Consultants, LLP

    Charleston, South Carolina

  • Allergic Disease and Asthma Center

    Greenville, South Carolina

  • University of Tennessee - Dept. of Pediatrics

    Memphis, Tennessee

  • Suzanne Bruce& Associates, PA

    Houston, Texas

  • Grand Parkway Pediatrics

    Sugar Land, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Novartis

    Investigative Site, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.